Life Sciences and Health Care Industry Outlook 2017
What are the trends for US life sciences and health care companies in the coming year?
With disruptors shifting the life sciences and health care landscape, organizations willing to make investments in innovative business models will have a positive outlook in 2017. Our latest set of outlook interviews explore factors that are likely to shape the life sciences and health care industry in the coming year and beyond.
- Health care providers
- Health plans
- Life sciences
- Additional perspectives
- Latest trends in health care
Health care providers: Which growth opportunities should companies prepare for in 2017?
Listen in as Mitch Morris, MD, vice chairman and US/global Health Care Providers leader, Deloitte Consulting, LLP, weighs in on the impact of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), health care industry disruptors, the value of analytics, as well as cost, regulatory pressures, and the possibilities of digital consumer engagement.
We can do more through telehealth and programs, monitoring and measuring people in a home setting than we’ve been able to do in the past. Through reminding patients to take their medication, we are really putting the power of health in the hands of the consumer and putting the patient truly at the center.
Health plans: How can health plans navigate a changing health care landscape?
Listen in as Greg Scott, national leader of Deloitte's Health Plans practice, discusses trends and developments in the health plans sector that are being impacted by an ever-growing wave of patient demands for value and technology-enabled care.
So health plans, as well as some of the more technologically savvy stakeholders in the US health care system, have some opportunities–as well as some challenges. Consumers are really focused on providers who understand who they are. They want personalized interactions, data at their fingertips, and physicians who are generally ready, willing, and able to have more productive encounters.
Life sciences: What opportunities and trends are on the horizon for the life sciences industry?
Managing pricing and costs, changing business models, focusing on customer engagement, and persevering through a changing regulatory environment are all on the horizon for life sciences companies in 2017.
For more on what is ahead for the life sciences industry, dig into our interview with Greg Reh, Deloitte’s global and US Life Sciences sector leader for consulting, audit, tax, and financial advisory services.
The establishment of evidence management capabilities is going to be key both in terms of optimizing R&D efforts, as well as providing the requisite data to demonstrate value, particularly within the context of outcomes-based contracting models.
Additional perspectives on life sciences and health care trends
An aging global population and chronic diseases are fueling the rising demand and associated spending of care and an increasing patient awareness, knowledge, and expectations are putting pressure on the development of costly clinical innovations. The Global Health Care Outlook explores trends and issues impacting sector organizations; and suggests considerations for stakeholders as they seek to deliver cost-effective high-value health care.
Regulatory Health Care Outlook
The post-election landscape leaves key regulatory areas such as the Affordable Care Act facing significant uncertainty, and no one knows for sure how things will turn out. In this report, we examine regulatory trends based on what we know now, with additional insights about high-level views on potential regulatory changes. What regulations should health care executives keep top of mind in 2017 and how can they prepare?
Explore the specific regulatory trends that might shape the health care industry in coming year and beyond in our forthcoming publication.
Global Life Sciences Outlook
Life sciences sector growth is closely tied to global health care expenditures which, in 2017 and successive years, are expected to be fueled by increasing demand from an aging population and the burgeoning prevalence of chronic and communicable diseases. This 2017 outlook reviews the current state of the global life sciences sector; explores trends and issues impacting market segments and individual organizations, and suggests considerations for stakeholders as they seek to grow revenue and market share.
Life Sciences Regulatory Outlook
Life sciences companies should prepare to face continued uncertainty in the regulatory landscape in 2017. With drug pricing in flux and regulations aimed at improving patient outcomes and value-based contacting in play, life sciences companies will likely need to adapt to the downstream impacts.
What might Donald Trump’s election mean for health care?
In November, Donald Trump was elected the 45th president of the United States and the Republicans retained majorities in both the Senate and the House. What does this portend for our health care system?
President-elect Trump ran on one main policy issue related to health care – to repeal the Affordable Care Act (ACA). Could he, together with a Republican-led Congress, do this? And what might his election mean more broadly for health insurance exchanges, value-based care initiatives, and consumers’ and employers’ desires for more affordable health care?
In today’s rapidly evolving marketplace environment, key business issues are converging with impacts felt across multiple industry sectors. What are the key trends, challenges, and opportunities that may affect your business and influence your strategy? Look for more perspectives and insights from some of Deloitte’s forward thinkers.
Health Care Current | November 10, 2016
Medicare Access and CHIP Reauthorization Act of 2015